BAKKACIMA BLOG

  COVID-19 vaccines made by  Johnson & Johnson(J&J) and Novavax  have also been shown to offer weaker protection against B.1.351 (also known as 501.V2), the SARS-CoV-2 variant that now causes the vast majority of all infections in South Africa, than against older variants. The vaccines’ efficacy against mild disease in South Africa was 57% for J&J and 49% for Novavax—lower than in any other country they were tested. The stakes are high globally for this particular vaccine because its makers, AstraZeneca and the University of Oxford, hope it will be widely used in developing countries; they project they can produce 3 billion doses this year for about $3 each, far more product at a far lower price than any other vaccine shown to offer protection against COVID-19. Madhi and the research team had planned to report the results on 8 February, but the  Financial Times  ran a story two days earlier based on a leaked copy of the findings. Madhi and his ...

  An elderly man in his 70s (American) collapsed and died on Sunday morning shortly after receiving a COVID-19 vaccine. The man fell as he left Manhattan's Jacob Javits Convention Center just 25 minutes after receiving his shot, New York State Health Commissioner Dr. Howard Zucker said in a statement.  He was pronounced dead at a local hospital shortly after he was rushed there. It's currently unclear if the man's death is linked to the vaccine, but an investigation is now underway. But, initial indications are that the man did not